Isomorphic Labs is preparing to initiate human trials of AI-designed drugs, according to president Colin Murdoch. The company, stemming from DeepMind's AlphaFold, aims to enhance drug design processes. Murdoch indicated that clinical trials for AI-assisted drugs are on the horizon. The company's developments in protein interaction modeling have the potential to revolutionize drug discovery, allowing for faster and more accurate medicine design. Isomorphic Labs, established in 2021, has made strategic collaborations with major pharmaceutical companies to bolster its drug discovery efforts.
There are people sitting in our office in King's Cross, London, working, and collaborating with AI to design drugs for cancer. That's happening right now.
The next big milestone is actually going out to clinical trials, starting to put these things into human beings. We're staffing up now. We're getting very close.
This was the inspiration for Isomorphic Labs. It really demonstrates that we could do something very foundational in AI that could help unlock drug discovery.
After years in development, human clinical trials for Isomorphic's AI-assisted drugs are finally in sight.
Collection
[
|
...
]